Tobacco Use Disorder

2
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

J&
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
1
1
Bupropion SRPhase 41 trial
CHERLPhase 11 trial
Active Trials
NCT00269009UnknownEst. Feb 2007
NCT00119210Terminated40Est. Mar 2006
BrainsWay
BrainsWayJerusalem, Israel
1 program
Deep Repetitive Transcranial Magnetic StimulationN/A
Alliance Pharmaceuticals
1 program
Fresh limeN/A1 trial
Active Trials
NCT01333202Completed100Est. Sep 2009
Pfizer
PfizerNEW YORK, NY
1 program
Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in HumansN/A1 trial
Active Trials
NCT01302262Completed10Est. Mar 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Johnson & JohnsonBupropion SR
Johnson & JohnsonCHERL
PfizerSmoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans
Alliance PharmaceuticalsFresh lime

Clinical Trials (4)

Total enrollment: 150 patients across 4 trials

Pilot Study of Bupropion for Smoking Cessation in Postpartum Non-breastfeeding Women

Start: Mar 2005Est. completion: Mar 200640 patients
Phase 4Terminated

CHERL, Connecting Primary Care Patients With Community Resources to Facilitate Behavior Change

Start: Jan 2006Est. completion: Feb 2007
Phase 1Unknown
NCT01302262PfizerSmoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Smoking-induced Dopamine Release: a [11C]-(+)-PHNO PET Study in Humans

Start: Feb 2011Est. completion: Mar 201310 patients
N/ACompleted

Fresh Lime Alone for Smoking Cessation

Start: Mar 2009Est. completion: Sep 2009100 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space